Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Avalon Bioventures
BioCentury | Nov 27, 2024
Emerging Company Profile
Valora: Blocking cancer’s immune evasion via glycan targeting
San Diego-based company’s antibody-lectin chimeras act as molecular decoys to disrupt cellular interactions
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Jul 22, 2024
Management Tracks
Nima Farzan named CEO of Latigo
Plus: Wu Changxiong succeeds Zhou Hua as CFO of Walvax, and updates from Hookipa, Janux, Akeso and Serina
BioCentury | Apr 30, 2024
Emerging Company Profile
Enlaza: Creating covalent biologics using engineered amino acids
Avalon-incubated biotech now has $161M to advance what could be the first covalent, irreversible protein drugs, starting in oncology
BioCentury | Apr 2, 2024
Finance
Biotech IPOs, Avalon & FDA at SCOTUS: a BioCentury podcast
Plus: assessing FDA’s first complete response letter for lack of confirmatory trial enrollment
BioCentury | Mar 25, 2024
Finance
Now a biotech pure-play, Avalon riding ‘sweat equity’ model to outsized returns
A smaller fund size can lead to a higher multiple — especially when a portfolio company such as Janux delivers promising early data
BioCentury | Sep 12, 2023
Emerging Company Profile
Arialys: targeting autoantibodies for CNS diseases, including rare encephalitis
With $58M seed round, Avalon-incubated start-up will also develop former Astellas antibody for other indications including psychosis
BioCentury | May 9, 2023
Deals
May 8 Quick Takes: EQRx reset brings end of China deals, layoffs
Plus: Legend’s $350M raise helps May follow-ons top April tally; ADC deals by Eisai-BlissBio, FibroGen-Fortis; and more
BioCentury | Dec 6, 2022
Finance
Avalon creates pure-play biotech VC with new $135M fund
After 11 funds that balanced tech and life sciences, the new Avalon BioVentures will preserve the firm’s sweat equity model
Items per page:
1 - 10 of 10